<p>Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin condition characterized by the formation of painful abscesses and tunnels under the skin. It typically occurs in areas where skin rubs together, such as the armpits, groin, buttocks, and under the breasts. The condition is progressive, and severe cases can lead to significant scarring and impairment in quality of life. While the exact cause of HS is not fully understood, it is believed to involve an abnormal immune response and is often associated with other conditions, such as Crohn&rsquo;s disease and metabolic syndrome. Early diagnosis and treatment are essential to control symptoms and prevent progression.</p>
<h2><strong>Hidradenitis Suppurativa Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Hidradenitis Suppurativa in the 7MM from 2020 to 2034 includes:</p>
<ul>
<li>Total Prevalent Cases of Hidradenitis Suppurativa in the US</li>
<li>Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the US</li>
<li>Gender-specific Cases of Hidradenitis Suppurativa in the US</li>
<li>Age-specific Cases of Hidradenitis Suppurativa in the US</li>
<li>Stage-specific Cases of Hidradenitis Suppurativa in the US</li>
<li>Treated Prevalent Cases of Hidradenitis Suppurativa in the US</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/hidradenitis-suppurativa-epidemiology"><span style="text-decoration: underline;"><strong>Hidradenitis Suppurativa Epidemiology</strong></span></a></h2>
<p>In 2023, the prevalence of Hidradenitis Suppurativa showed distinct trends across the 7MM:</p>
<ul>
<li>The total Hidradenitis Suppurativa prevalent cases in the 7MM were nearly 6.2 million. These cases are anticipated to increase by 2034.</li>
<li>The US accounted for the highest number of Hidradenitis Suppurativa diagnosed prevalent cases with nearly 877,600 cases in 2023.</li>
<li>Among the EU4 and the UK, Germany accounted for the highest number of Hidradenitis Suppurativa diagnosed prevalent cases, whereas Spain had the lowest number.</li>
<li>In the US, EU4, and the UK, Hidradenitis Suppurativa was slightly more common in females (~75%) than in males (~25%). Conversely, in Japan, males represented nearly 70% of the total cases, while females accounted for around 30%.</li>
<li>Age-specific data revealed that Hidradenitis Suppurativa was most prevalent in the age group of 30&ndash;39 years, which accounted for nearly 26% of the total diagnosed cases in the US.</li>
<li>Among the different Hurley stages, Hurley Stage I was the most prevalent, with approximately 480,000 cases in 2023 in the US.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market"><span style="text-decoration: underline;"><strong>Hidradenitis Suppurativa Market</strong></span></a></h2>
<p>In 2023, the total Hidradenitis Suppurativa market size was nearly USD ~1.4 billion in the 7MM.</p>
<h2>Hidradenitis Suppurativa Market Drivers</h2>
<ul>
<li>The emergence of novel therapies such as Povorcitinib (INCB054707), Izokibep, and RINVOQ (upadacitinib) offers targeted treatment options, which are expected to improve patient outcomes and drive market growth.</li>
<li>Increasing awareness about the condition and improved diagnostic methods are expected to contribute to earlier diagnosis and treatment, expanding the market for Hidradenitis Suppurativa therapies.</li>
</ul>
<h2>Hidradenitis Suppurativa Market Barriers</h2>
<ul>
<li>The complexity of diagnosing and treating Hidradenitis Suppurativa, due to its variable presentation and progression, presents challenges in developing standardized treatment regimens and clinical trials.</li>
<li>The high cost of newer therapies and challenges related to their accessibility in some regions may hinder the widespread adoption of treatments.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/hidradenitis-suppurativa-pipeline-insight"><span style="text-decoration: underline;"><strong>Hidradenitis Suppurativa Emerging Therapies</strong></span></a></h2>
<ul>
<li>Povorcitinib (INCB054707)</li>
<li>Izokibep</li>
<li>RINVOQ (upadacitinib)</li>
<li>Lutikizumab (ABT-981)</li>
<li>Sonelokimab (M1095)</li>
<li>Spesolimab</li>
<li>Brepocitinib</li>
<li>Eltrekibart</li>
<li>Ruxolitinib 1.5% Cream</li>
<li>SAR-444656/KT-474</li>
<li>Orismilast</li>
</ul>
<p>And others</p>
<h2><strong>Hidradenitis Suppurativa Key Players</strong></h2>
<ul>
<li>Incyte Corporation</li>
<li>ACELYRIN</li>
<li>AbbVie</li>
<li>MoonLake Immunotherapeutics</li>
<li>Boehringer Ingelheim</li>
<li>Priovant Therapeutics</li>
<li>Eli Lilly</li>
<li>Sanofi</li>
<li>Kymera Therapeutics</li>
<li>UNION Therapeutics</li>
</ul>
<p>And others</p>

Hidradenitis suppurativa Market

Hidradenitis suppurativa Infographics

Hidradenitis Suppurativa Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.